ClinicalTrials.gg
RecruitingNCT05724719Updated Oct 17, 2024

Seizure Recurrence After Unprovoked First Seizure

An observational study in Single Seizure and Epilepsy, sponsored by Dr. Gavin Winston. Recruiting at 2 sites in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Dr. Gavin Winston · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
275
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Seizures with a site in Canada — 9 open to participants now, 12 under way, 7 of them phase 3. Seizures · Canada.

Planned enrollment
4th of 11
275 · median 82
Started
2023
with 2 others
Observational
11 of 61
3 open now
Primary completion
2026-09
later than 2 of 11 live
Registered
50th of 61
by date

Among the 61 studies in Seizures with a site in Canada, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2023, is one of 11 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 50th registered.

Seizures

766 studies on the registry are indexed under Seizures; 133 are open to participants now.

Browse Seizures studies →

Open to participants now

9 of the 61 studies in Seizures with a site in Canada are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Seizures with a site in Canada, or all of them as a file.
02

Study summary

One in 10 people have a seizure during their life. Usually no cause is identified. Seizures without an identified cause are called unprovoked first seizure (UFS). Most people with UFS do not have further seizures. Being able to predict the risk of more seizures as soon as possible would help doctors decide whether to suggest treatment after UFS.

Studies show that seizures are associated with changes in brain structure and function that are difficult to detect with standard assessments but can be detected with advanced techniques. Changes in connections between brain regions are also linked to subtle problems in thinking and mood.

The investigators will examine brain connections using detailed brain scans, thinking, and mood in people with UFS and develop an accurate method for calculating the risk of further seizures.

200 adult patients and 75 matched healthy controls from the Halifax and Kingston First Seizure Clinics will undergo cognitive screening assessment of major cognitive domains, MRI imaging including structural scans, resting-state functional MRI (rsfMRI) and diffusion-weighted imaging (DWI), and EEG.

Seizure recurrence will be assessed prospectively and a multimodal machine learning model will be trained to predict seizure recurrence at 12 months.

03

Conditions studied

  • Single Seizure
  • Epilepsy

Keywords

  • Cognition
  • Mood
  • Brain Connectivity
  • Neuroimaging
  • Neurophysiology
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients aged 18-65 years old with unprovoked first seizure; age, sex and education-matched healthy controls.

Multi-centre, the study population will consist of adults from across Atlantic Canada, and South-Eastern Ontario.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • This study will consider adult patients between the ages of 18-65 years seen in the First Seizure Clinics in Halifax and Kingston with unprovoked first seizure.
  • The investigators will also include a sample of age, sex, and education-matched healthy controls with the same exclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Individuals over the age of 65 will not be included to reduce the probability of including individuals with early dementia.
  • The investigators will also exclude individuals who, upon assessment during their first clinic appointment, are determined to have non-epileptic events, recurrent events or diagnosis of epilepsy (e.g. based on abnormal CT or EEG), provoked seizure (e.g. medication, substance misuse, metabolic), acute symptomatic seizures, those with an existing prescription for antiseizure drugs, significant CNS comorbidity that may affect cognition and brain networks (e.g. progressive neurological disorder, MS), previous neurosurgery, or to MRI.
  • Finally, although there is no known risk to a fetus from MRI scanning, as is standard in research studies involving MRI, pregnant participants will be excluded and those that suspect that they may be pregnant require a negative pregnancy test before scanning.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
275 participants (estimated)
Patient registry
No

Groups and cohorts

  • Unprovoked First Seizure (UFS)

    Participants will undergo cognitive screening assessment, MRI imaging and EEG (if not already done) within 2-4 weeks of the initial First seizure clinic visit. Seizure recurrence will be monitored by a diary provided to each participant with details of the research team to contact in the event of a seizure. A researcher via perform telephone reminders at 3, 6, 9 and 12 months following the seizure. The primary outcome will be seizure recurrence at 12 months.

  • Healthy Controls

    Healthy control participants will complete the same neuropsychological battery, MRI scans and EEG protocols to evaluate baseline level of impairment in a healthy population and for the group comparisons of UFS to healthy controls to establish the changes already present at initial presentation with UFS.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Seizure Recurrence after Unprovoked First Seizure

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
  • Dalhousie University and Nova Scotia Health Authority
    Halifax, Nova Scotia, Canada
    Recruiting
  • Queen's University and Kingston Health Sciences Centre
    Kingston, Ontario K7L 2V7, Canada
    Recruiting
    • Christopher Hlynialuk, MSc · Contacthlynialuk.c@queensu.ca · 613-533-6000
    • Gavin P Winston, BM BCh, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Sep 2026, 37 months after the start.

Of 53 non-industry observational studies under Seizures, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 18. This study's planned 37 months is below that.

Counting every sponsor, half of 80 studies reached it within 37 months; a quarter within 18 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 13, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05724719
Lead sponsor
Dr. Gavin Winston
Collaborators
Canadian Institutes of Health Research (CIHR), Nova Scotia Health Authority
Responsible party
Dr. Gavin Winston (Dr. Gavin Winston, Associate Professor, Dept. of Medicine, Queen's University, Faculty-Centre for Neuroscience, Queens University, Queen's University) — Sponsor-investigator
First posted
Feb 13, 2023
Start date
Aug 1, 2023
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Oct 17, 2024

Study contacts

Christopher Hlynialuk, MSc
Contact
hlynialuk.c@queensu.ca
613-533-6000 ext. 79750
Gavin P Winston, BM BCh, PhD
principal investigator · Queen's University
Antonina Omisade, BA, PhD
principal investigator · Nova Scotia Health Authority

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion